https://www.selleckchem.com/products/pt2977.html
In addition, MHO seems to be a transient phenotype further justifying therapeutic weight loss attempts even in this subgroup which might not benefit from reducing body weight to the same extent as patients with unhealthy obesity. MHO represents a model to study mechanisms linking obesity to cardiometabolic complications. MHO should not be considered a safe condition, which does not require obesity treatment, but may guide decision making for a personalized and risk-stratified obesity treatment. © Endocrine Society 2020.Recent approaches
Mi piace
Commento
Condividi
